Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

CV Therapeutics Raising $288M Via Stock, Notes

June 30, 2005

By Jennifer Boggs

Cougar Adds Seocalcitol, Fattens Oncology Pipeline

June 29, 2005

By Jennifer Boggs

Cougar Adds Seocalcitol, Fattens Oncology Pipeline

June 29, 2005

By Jennifer Boggs

Metabasis Signs AMPK Deal With Merck Worth Up To $74M

June 28, 2005

By Jennifer Boggs

Metabasis Signs AMPK Deal With Merck Worth Up To $74M

June 28, 2005

By Jennifer Boggs

Salix Plans To Acquire InKine In Stock Deal Valued at $190M

June 27, 2005

By Jennifer Boggs

Salix Plans To Acquire InKine In Stock Deal Valued at $190M

June 27, 2005

By Jennifer Boggs

Amoxicillin Pulsys Misses In Phase III Trial; Advancis Falls

June 17, 2005

By Jennifer Boggs

Immtech's SPA Set For Pivotal Trial Of Anti-Infective Product

June 17, 2005

By Jennifer Boggs

Immtech's SPA Set For Pivotal Trial Of Anti-Infective Product

June 17, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...